

Finerenone (KERENDIA) in Heart Failure with Preserved Ejection Fraction (HFpEF) and Mildly Reduced Ejection Fraction (HFmrEF) Criteria for Use November 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If any of the following are selected, the patient will NOT meet criteria for finerenone.

- Serum potassium level greater than 5.0 mEq/L
- Estimated glomerular filtration rate (eGFR) less than 25 mL/min/1.73m
- Severe hepatic impairment (e.g., Child-Pugh class C)
- Concomitant treatment with strong CYP3A4 inhibitors or strong or moderate CYP3A4 inducers
- Adrenal insufficiency
- Lactating

Inclusion Criteria

All the following criteria must be selected to meet criteria.

- Diagnosis of symptomatic heart failure with a left ventricular ejection fraction (LVEF) of 40% or greater¹
- Receiving treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor or unable to use an SGLT2 inhibitor
- Intolerance or unable to use spironolactone²

Additional Inclusion Criteria

Select if applicable.

- For females who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy
1. If finerenone is being requested for type 2 diabetes mellitus and chronic kidney disease, please reference VHA PBM Criteria for this indication.
 2. Eplerenone may be considered before finerenone in patients who experience intolerance to spironolactone due to gynecomastia.

Original: November 2025

Contact: Lisa Longo, PharmD, BCPS, National Program Manager, VA Pharmacy Benefits Management Services – Formulary Management (12PBM)
